ClinicalTrials.gg

Program

Sodium Chloride

Also written as “Custodiol”, “HalfLytely” and “Sodium chloride”.

Its studies are mostly in Osteoarthritis, Knee · COVID-19 · Aortic Valve Disease · Heart Failure · Corneal Edema, led by 5 companies.

Furthest: phase 4, since Aug 31, 20126 company-led studies, 1 open or runningNext primary completion: Apr 1, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novo Nordisk20 open or runningphase 1since Aug 31, 2012Aug 31, 2012none ahead
aspen-global-incorporated10 open or runningphase 4since Jan 29, 2019Jan 29, 2019none ahead
Eye-yon Medical10 open or runningno phasesince Jan 11, 2016Jan 11, 2016none ahead
Lumos Pharma10 open or runningphase 1since Dec 10, 2017Dec 10, 2017none ahead
Nova Vita Laboratory11 open or runningphase 2since Sep 17, 2024Sep 17, 2024Apr 1, 2027phase 2 · NCT06606561

Also a collaborator on its studies: parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 31, 2012First study: phase 1 study in Diabetes MellitusNew to Novo NordiskNovo Nordisk · NCT01680328 · 82 enrolled · Germany
  2. Nov 6, 2012Phase 1 study in Diabetes MellitusNovo Nordisk · NCT01730014 · 70 enrolled · Germany
  3. Jan 11, 2016Eye-yon Medical's first study: no phase study in Corneal EdemaNew to Eye-yon MedicalEye-yon Medical · NCT02660151 · 68 enrolled · Israel, Poland
  4. Dec 10, 2017Lumos Pharma's first study: phase 1 study in HealthyNew to Lumos PharmaLumos Pharma · NCT03372239 · 48 enrolled · Canada
  5. Jan 29, 2019aspen-global-incorporated's first study: phase 4 study in Injection Site ReactionNew to aspen-global-incorporatedaspen-global-incorporated · NCT03841396 · 15 enrolled
  6. Sep 17, 2024Nova Vita Laboratory's first study: phase 2 study in Osteoarthritis, KneeNew to Nova Vita LaboratoryNova Vita Laboratory · NCT06606561 · 24 planned · United States

Ahead

  1. Apr 1, 2027Primary completion: phase 2 study in Osteoarthritis, KneeNova Vita Laboratory · NCT06606561

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06606561Osteoarthritis, Knee · United States2Not yet recruitingNova Vita LaboratoryApr 1, 202724
NCT03841396Injection Site Reaction4Completedaspen-global-incorporatedJul 15, 201615
NCT03372239Healthy · Canada1CompletedLumos PharmaJan 25, 201848
NCT02660151Corneal Edema · Israel, Poland–CompletedEye-yon MedicalOct 201868
NCT01730014Diabetes Mellitus · Germany1CompletedNovo NordiskJul 201370
NCT01680328Diabetes Mellitus · Germany1CompletedNovo NordiskOct 201282

How it is read

Names in the registry

  • “Custodiol”, 4 entries
  • “HalfLytely”, 3 entries
  • “Sodium chloride”, 2 entries
  • “PLENVU®”, 1 entry
  • “0.9% Sodium Chloride Injection, USP”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.